As­traZeneca, CRISPR tools sup­pli­er ink gene edit­ing en­zyme li­cens­ing deal

Genome en­gi­neer­ing busi­ness Syn­thego will have ac­cess to As­traZeneca’s CRISPR gene edit­ing en­zyme in its sec­ond li­cens­ing agree­ment in the past year.

Syn­thego plans on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER